Abbott Laboratories to Spin Off Nutrition Business
The separation of the nutrition unit into an independent company follows over $1 billion in legal settlements.
Updated on Oct. 21, 2026 in Public Companies
Live Poll
Do you believe corporate spin-offs generally lead to better results for customers and shareholders?
Abbott Laboratories will spin off its nutrition business, which houses brands like Similac and Ensure, into an independent publicly traded company. The separation, planned for completion by the end of 2027, follows significant operational and legal hurdles for the unit.
Why it matters
The move aims to insulate the core Abbott enterprise from the legal and manufacturing risks that have plagued its nutrition division, which recently faced major settlements and product recalls. This restructuring highlights the operational pressure that product safety failures place on long-term corporate strategy.
Abbott faces a combined $1.055 billion in legal costs, including $670 million for infant formula lawsuits and $385 million for manufacturing allegations. Shares reacted with a 4% pre-market dip on October 21, adding to a year-to-date decline of more than 18%.
The players
Abbott Laboratories
A global healthcare and medical devices company with a portfolio spanning diagnostics, nutrition, and cardiovascular products.
Daniel Salvadori
The incoming chief executive officer of the future independent nutrition company.
The details
The nutrition division, which includes Pedialyte, Similac, and Ensure, has struggled with widespread recalls and a nationwide supply shortage dating back to 2022. Abbott will execute the separation through a tax-free distribution to existing shareholders, with Daniel Salvadori tapped to lead the new company. This transition is expected to isolate these liabilities without altering Abbott's 2026 or 2027 earnings guidance.
Timeline
2022: Nationwide infant formula shortage occurred.
August 2026: Abbott agreed to pay $670 million in lawsuits.
September 2026: Abbott settled manufacturing allegations for $385 million.
October 21, 2026: Abbott announced the nutrition unit spin-off.
End of 2027: Expected completion of the spin-off.
Market Landscape
The spin-off marks a structural response to the operational fragility exposed by the 2022 nationwide infant formula shortage. It aligns with a broader industry trend of separating legacy consumer-facing business units from medical technology companies to decouple risk profiles.
Operators should watch the new entity's performance to see if it can successfully unburden itself from the legacy litigation and manufacturing costs that weighed on the parent firm. For businesses managing similar recall or safety-linked liabilities, this move provides a benchmark for using corporate restructuring to protect core margins.
The takeaway
Large-scale corporate spin-offs often serve as a strategy to isolate operational failures or legal liabilities from a parent company's market valuation. Monitor the new entity's upcoming regulatory filings to assess whether the separation effectively stabilizes its operational cost structure.
What happens next
The company expects to finalize the separation of its nutrition business by the end of 2027.
Further reading
For more on corporate structural changes, see Public Companies.
Live Poll
Do you believe corporate spin-offs generally lead to better results for customers and shareholders?
